DORC is proud to announce the launch of a significant enhancement to the EVA surgical system. CE mark was obtained in December 2018 and the enhancement is already in clinical use at several sites in Europe. It will be commercially available from March 2019 in CE markets with US and Japan to follow. From March 2019 the enhancement will be implemented in all new EVA systems and the enhancements can also be retro-fitted to all existing EVA posterior and combined systems (subject to regulatory clearance per market).
The enhancement has been developed in close collaboration with users, it delivers both OR efficiency and surgical performance enhancements to users. The benefits of the enhancement include the following.
Firstly, the EVA footswitch has been completely redesigned, control of the EVA endolaser is now integrated into the main footswitch providing seamless switching between vitrectomy to laser and eliminating the need for a secondary laser pedal. As well as improving efficiency, any surgeon can operate independent of tech support when switching to laser. The new footswitch also has a range of ergonomic enhancements to ensure optimal surgeon comfort during longer procedures. These include buttons that can be reached without removing the foot from the pedal, a new heel rest to provide a more comfortable resting point and a lower angle of operation. It is also the first surgical system footswitch to feature interchangeable inlays (patent pending) allowing the surgeon to choose from 4 currently available options that can be easily switched. DORC also plans to offer customizable inlays at a future date.
After performing his first procedures with the upgrade, Prof Claus Eckardt (Klinikum Frankfurt Höchst – Germany) commented “The redesigned footpedal significantly improves the comfort of working with EVA. The ergonomics are much better, such as a better angle of operation and a new heel rest design adapted for different foot positions. In addition, the integration of laser control in the main pedal is wonderful, eliminating the need for a secondary laser pedal”.
Secondly, the EVA LED light source has been improved to provide at least 30% more light for 25/27g versus the current LED light. When combined with the enhanced 27g light fibres launched in 2018, this provides a further total enhancement in light output vs the previous technology available*. This has been developed in response to demand for improved illumination from the growing number of surgeons working with 27g. After performing his first cases with the upgraded light source, Prof Peter Stalmans (UZ Leuven – Belgium) commented, “With the upgraded LED light source, illumination is no longer a limit to perform 27G surgery, plus, using the new foot pedal, surgery is no longer interrupted when switching to endolaser treatment”.
“This upgrade is a significant milestone in the development of the EVA platform” commented Thierry Leclercq, CEO DORC International. “The light output improvement delivers market leading illumination and ensures ‘no compromise’ 27g surgery, plus the redesigned footswitch maximizes surgeon control in the OR. I am particularly pleased that we have been able to make this innovation available for retro-fitting to existing EVA systems”
The EVA upgrade will be premiered during live surgery broadcast to the upcoming Osaka Retina Meeting (25.05.2019 – http://www.congre.co.jp/retina2019/en/index.html) including live surgery with EVA broadcast from Frankfurt with Prof. Eckardt and Leuven with Prof. Stalmans – both users of EVA since launch. This will be followed by live surgery at the FLORETINA meeting (06-09.06.2019 – https://www.floretina2019.it/)
Contact for further information / interviews / comment:
Angelique van Rutten – email@example.com
James Burckhardt – firstname.lastname@example.org
*Total Light output remains within the EVA specification of maximum 40 lumens